Thalidomide-derived immunomodulatory drugs as therapeutic agents

Bibliography

• MCBRIDE WG: Teratogenic action of thalidomide. Lancet (1978)1:1362.
   PubMed Web of Science ®Google Scholar
• FULLERTON PM, KREMER M: Neuropathy after intake of thalidomide (distava0. Br. Med. (1961) 5256:855–858.
   Google Scholar
• SHESKIN J: Further observation with thalidomide in lepra reactions. Lex: Rev (1965) 36:183–187.
   PubMedGoogle Scholar
• PARIDA SK, GRAU GE: Role of TNF in immunopathology of leprosy Res. Immunol (1993) 144:376–384.
   Web of Science ®Google Scholar
• SAMPAIO EP, SARNO EN, GALILLY R,COHN ZA, KAPLAN G: Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. I Exp. Med. (1991) 173:699–703.
   PubMed Web of Science ®Google Scholar
• •Important paper demonstrating that thalidomide inhibits TNF-a production by stimulated monocytes, and opening up a rationale for clinical use in the treatment of TNF-a-mediated disease.
   Google Scholar
• DAVIES FE, RAJE N, HIDESHIMA T et al: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood (2001) 98:210–216.
   PubMed Web of Science ®Google Scholar
• MOREIRA AL, SAMPAIO EP, ZMUIDZINAS A, FRINDT P, SMITH KA, KAPLAN G: Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. I Exp. Med. (1993) 177:1675–1680.
   PubMed Web of Science ®Google Scholar
• EIGLER A, SINHA B, HARTMANN G, ENDRES S: Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today (1997) 18:487–492.
   PubMedGoogle Scholar
• SLUITER W, PIETERSMA A, LAMERS JM, KOSTER JF: Leukocyte adhesion molecules on the vascular endothelium: their role in the pathogenesis of cardiovascular disease and the mechanisms underlying their expression. Cardiovasc. Pharmacol (1993) 22\(Suppl. 4):S37–S44.
   Google Scholar
• VANDERSLICE P, MUNSCH CL, RACHAL E et al.: Angiogenesis induced by tumor necrosis factor-agr; is mediated by alpha4 integrins. Angiogenesis (1998) 2:265–275.
   PubMedGoogle Scholar
• JOURDAN M, TARTE K, LEGOUFFE E, BROCHIERJ, ROSSI JF, KLEIN B: Tumor necrosis factor is a survival and proliferation factor for human myeloma cells Eur. Cytokine Netw. (1999) 10:65–70.
   PubMed Web of Science ®Google Scholar
• KATERINAKI E, EVANS GS,LORIGAN PC, MACNEIL S: TNF-a increases human melanoma cell invasion and migration in vitro: the role of proteolyticenzymes. Br. Cancer (2003) 89:1123–1129.
   Google Scholar
• MALIK ST, NAYLOR MS, EAST N, OLIFF A, BALKWILL FR: Cells secreting tumour necrosis factor show enhanced metastasis in nude mice Eur. J Cancer (1990) 26:1031–1034.
   Web of Science ®Google Scholar
• MALIK ST: Tumour necrosis factor: roles in cancer pathophysiology Semin. Cancer Biol. (1992) 3:27–33.
   PubMedGoogle Scholar
• FERRARI R: The role of TNF in cardiovascular disease. Pharmacol Res. (1999) 40:97–105.
   PubMed Web of Science ®Google Scholar
• GRELL M, WAJANT H,ZIMMERMANN G, SCHEURICH P: The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor Proc. Natl. Acad. Sci. USA (1998) 95:570–575.
   PubMed Web of Science ®Google Scholar
• NOGUCHI T, SHIMAZAWA R, NAGASAWA K, HASHIMOTO Y: Thalidomide and its analogues as cyclooxygenase inhibitors. Bioorg. Med. Chem. Lett. (2002) 12:1043–1046.
   PubMed Web of Science ®Google Scholar
• GASPARINI G, LONGO R, SARMIENTO R, MORABITO A: Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol (2003) 4:605–615.
   PubMed Web of Science ®Google Scholar
• DANIEL TO, LIU H, MORROW JD, CREWS BC, MARNETTThromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis Cancer Res. (1999) 59:4574–4577.
   Google Scholar
• FUJITA J, MESTRE JR, ZELDIS JB, SUBBARAMAIAH K,DANNENBERG AJ: Thalidomide and its analogues inhibit lipopolysaccharide-mediated Iinduction of cyclooxygenase-2. Clin. Cancer Res. (2001) 7:3349–3355.
   PubMed Web of Science ®Google Scholar
• HASLETT PA, CORRAL LG, ALBERT M, KAPLAN G: Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. Exp. Med. (1998) 187:1885–1892.
   PubMed Web of Science ®Google Scholar
• ••First report of thalidomide-mediatedT cell costimulation in vitro, which opened up a new therapeutic avenue and helped to explain some unexpected clinical observations.
   Google Scholar
• DREDGE K, MARRIOTT JB,TODRYK SM et al.: Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Thl-type immunity. j. Immunol (2002) 168:4914–4919.
   Google Scholar
• •First report showing T cell costimulatory activity of IMiDs in vivo, and the use of this property in the augmentation of antiturnour immunity when administered in combination with a whole cell vaccine.
   Google Scholar
• BARTLETT JB, MICHAEL A,CLARKE IA et al.: Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br. J. Cancer (2004) 90:955–961.
   Google Scholar
• •First report of a lenalidomide Phase I study in patients with solid tumours.
   Google Scholar
• SCHEY SA, FIELDS P, BARTLETT JB et al.: Phase I study of animmunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. .1 Clin. Oncol (2004) 22:3269–3276.
   Google Scholar
• •First report of a Phase I study of CC-4047 (ACTIMID) in patients with relapsed MM.
   Google Scholar
• MARRIOTT JB, CLARKE IA,DREDGE K, MULLER G, STIRLING D, DALGLEISH AG: Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNER2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin. Exp. Irnmunol. (2002) 130:75–84.
   PubMed Web of Science ®Google Scholar
• STREET SE, HAYAKAWA Y, ZHAN Y et al.: Innate immune surveillance of spontaneous b cell lymphomas by natural killer cells and fgammaHdeltal T cells. Exp. Med. (2004) 199:879–884.
   PubMed Web of Science ®Google Scholar
• MITSIADES N, MITSIADES CS, POULAKI V et al.: Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood (2002) 99:4525–4530.
   PubMed Web of Science ®Google Scholar
• HIDESHIMA T, CHAUHAN D, SHIMA Y et al.: Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood (2000) 96:2943–2950.
   PubMed Web of Science ®Google Scholar
• ••An important paper showing the inductionof growth arrest of chemoresistant myeloma cell lines and patient myeloma cells by thalidomide and IIVIiD analogues.
   Google Scholar
• RAJE N, ANDERSON KC: Thalidomide and immunomodulatory drugs as cancer therapy. Carr: Opin. Oncol (2002) 14:635–640.
   PubMed Web of Science ®Google Scholar
• MOREIRA AL, FRIEDLANDER DR, SHIF B, KAPLAN G, ZAGZAG D: Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation M vitro. Neurooncol. (1999) 43:109–114.
   PubMed Web of Science ®Google Scholar
• D'AMATO RJ, LOUGHNAN MS, FLYNN E, FOLKMAN J: Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA (1994) 91:4082–4085.
   PubMed Web of Science ®Google Scholar
• ••Seminal report showing thatthalidomide is antiangiogenic, and paving the way for clinical use in the treatment of various cancers.
   Google Scholar
• KENYON BM, BROWNE F,D'AMATO RJ: Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp. Eye Res. (1997) 64:971–978.
   PubMed Web of Science ®Google Scholar
• DREDGE K, MARRIOTT JB, MACDONALD CD et al: Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br. Cancer (2002) 87:1166–1172.
   Google Scholar
• GUPTA D, TREON SP, SHIMA Y et al.: Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.17. Leukemia (2001) 15:1950–1961.
   Google Scholar
• YANG L, DAN HC, SUN M et al.: Akt/ protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancercells overexpressing Akt. Cancer Res. (2004) 64:4394–4399.
   PubMed Web of Science ®Google Scholar
• SIN GHAL S, MEHTA J, DESIKAN R et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl. J. Med. (1999) 341:1565–1571.
   PubMed Web of Science ®Google Scholar
• ••Important clinical paper showing for thefirst time the clinical efficacy of thalidomide in MM patients.
   Google Scholar
• BERTOLINI F, MINGRONE W, ALIETTI A et al.: Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. Ann. Oncol (2001) 12:987–990.
   Google Scholar
• STEINS MB, PADRO T, BIEKER R et al: Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood (2002) 99:834–839.
   PubMed Web of Science ®Google Scholar
• RAJKUMAR V, HAYMAN S, GERTZ M et al.: Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. .1 Clin. Oncol (2002) 20:4319–4323.
   Google Scholar
• WEBER D, RANKIN K, GAVINO M et al.: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. Clin. Oncol (2003) 21:16–19.
   Web of Science ®Google Scholar
• RICHARDSON P, SCHLOSSMAN R, JAGANNATH S et al.: A multicenter Phase II dose escalation study of thalidomide in patients with relapsing multiple myeloma post-SCT. Mayo Clin. Proc. (2004) 79:875–882.
   PubMed Web of Science ®Google Scholar
• ZANGARI M, TRICOT G, ZELDIS J, EDDLEMON P, SAGHAFIFAR F, BARLOGIE B: Results of Phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT). [abstract]. Blood (2001) 98:775a.
   Google Scholar
• RICHARDSON PG, SCHLOSSMAN RL, WELLER E et al.: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood (2002) 100:3063–3067.
   PubMed Web of Science ®Google Scholar
• •First published paper showing efficacy of lenalidomide in MM patients.
   Google Scholar
• BARTLETT JB, DREDGE K, DALGLEISH AG: The evolution of thalidomide and its IMiD derivatives as anticancer agents. NatRev.Cancer (2004) 4:314–322.
   PubMed Web of Science ®Google Scholar
• ••Comprehensive history of theevolution of thalidomide and IMiDs as anticancer drugs.
   Google Scholar
• RICHARDSON P, JAGANNATH S, SCHLOSSMAN R et al.: A multi-center, randomized, phase II study to evaluate the efficacy and safety of 2 CDC-5013 dose regimens when used alone or in combination with dexamethasone (Dex) for the treatment of relapsed or refractory multiple myeloma (MM). Blood (2003)102:Abstract 825.
   Google Scholar
• RICHARDSON P, ANDERSON K: Immunomodulatory analogs of thalidomide: an emerging new therapy inmyeloma. Clin. amyl. (2004) 22:3212–3214.
   Web of Science ®Google Scholar
• •Editorial that reviews results to date with CC-4047 and lenalidomide in MM trials.
   Google Scholar
• LIST AF, KURTIN S,GLINSMANN-GIBSON B et al.: Efficacy and safety of CC5013 for treat ment of anemia in patients with myelodysplastic syndromes (MDS). Blood (2003) 102:Abstract 641.
   Google Scholar